Cis­platin, car­bo­platin short­ages raise ques­tions about im­pact on clin­i­cal tri­als 

At least two small biotechs have halt­ed clin­i­cal tri­als due to short­ages of cis­platin and car­bo­platin amid on­go­ing sup­ply is­sues for the chemother­a­pies com­mon­ly used …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER